Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
divestment
Pharma
Even through its remake, Alkermes retains upward trajectory: CEO
Alkermes is showcasing its rare set of attributes as a pure-play neuroscience biotech that is self-funded and has an intriguing pipeline program.
Kevin Dunleavy
Jan 13, 2025 7:36am
Hutchmed inks $608M asset sale to focus on ADC development
Jan 2, 2025 11:10am
Lonza aims to shed capsules business, restructure CDMO offerings
Dec 12, 2024 8:58am
Coherus sells Neulasta biosimilar to Intas for up to $558M
Dec 3, 2024 4:16pm
Pfizer explores sale of hospital drugs unit: Reuters
Nov 12, 2024 11:09am
Sanofi moves to sell 50% stake in €16B consumer health unit
Oct 21, 2024 11:34am
